Robert W. Baird Reiterates Buy Rating for EXACT Sciences (NASDAQ:EXAS)

Robert W. Baird reissued their buy rating on shares of EXACT Sciences (NASDAQ:EXAS) in a research report released on Wednesday morning, TipRanks reports.

Several other equities research analysts have also commented on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $120.00 price target on shares of EXACT Sciences in a report on Wednesday. Dougherty & Co began coverage on shares of EXACT Sciences in a report on Friday, December 13th. They issued a buy rating and a $120.00 price target on the stock. Stifel Nicolaus began coverage on shares of EXACT Sciences in a report on Thursday, November 14th. They issued a buy rating and a $110.00 price target on the stock. Citigroup began coverage on shares of EXACT Sciences in a report on Monday, January 6th. They issued a buy rating and a $120.00 price target on the stock. Finally, Bank of America reaffirmed a buy rating and issued a $135.00 price target on shares of EXACT Sciences in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. EXACT Sciences has a consensus rating of Buy and a consensus target price of $121.00.

Shares of EXAS opened at $98.18 on Wednesday. The firm has a market capitalization of $12.75 billion, a PE ratio of -134.49 and a beta of 1.36. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.75 and a quick ratio of 2.63. EXACT Sciences has a 1-year low of $75.35 and a 1-year high of $123.99. The company’s fifty day moving average price is $94.13 and its 200-day moving average price is $97.43.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.54 EPS for the quarter, beating the consensus estimate of ($0.37) by $0.91. EXACT Sciences had a negative net margin of 9.59% and a negative return on equity of 28.15%. The company had revenue of $295.58 million for the quarter, compared to analyst estimates of $294.39 million. As a group, research analysts anticipate that EXACT Sciences will post -1.25 EPS for the current fiscal year.

In other news, insider G Bradley Cole sold 10,000 shares of the stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $90.30, for a total transaction of $903,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of EXAS. Artisan Partners Limited Partnership boosted its stake in shares of EXACT Sciences by 20.7% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,191,714 shares of the medical research company’s stock worth $202,690,000 after acquiring an additional 375,796 shares in the last quarter. Marshall Wace North America L.P. purchased a new stake in shares of EXACT Sciences during the 4th quarter worth about $33,163,000. Factory Mutual Insurance Co. purchased a new stake in shares of EXACT Sciences during the 4th quarter worth about $27,181,000. D1 Capital Partners L.P. purchased a new stake in shares of EXACT Sciences during the 4th quarter worth about $25,432,000. Finally, Spyglass Capital Management LLC boosted its stake in shares of EXACT Sciences by 205.5% during the 4th quarter. Spyglass Capital Management LLC now owns 387,117 shares of the medical research company’s stock worth $35,801,000 after acquiring an additional 260,397 shares in the last quarter. 87.01% of the stock is currently owned by institutional investors and hedge funds.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: Treasury Bonds

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit